KYNTRA BIO, INC. Contract Liability (Deferred Revenue)
KYNTRA BIO, INC. (KYNB) had Contract Liability (Deferred Revenue) of $5.42 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Contract with Customer, Liability, Current $5.42M.
- 2026-03-31: Contract with Customer, Liability, Current $5.68M.
- 2025-12-31: Contract with Customer, Liability, Current $5.31M.
- 2025-09-30: Contract with Customer, Liability, Current $5.10M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $5.42M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $5.68M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $5.31M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $5.10M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $27.31M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $22.51M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $27.29M 10-K · filed 2026-03-16 |
| 2024-09-30 | $28.86M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $9.55M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $12.86M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $12.74M 10-K · filed 2025-03-17 |
| 2023-09-30 | $7.33M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $7.49M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $16.50M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $12.74M 10-K · filed 2024-02-26 |
| 2022-09-30 | $7.36M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $6.90M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $4.74M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $15.86M 10-K · filed 2023-02-27 |
| 2021-09-30 | $23.26M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $25.23M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $10.72M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $6.55M 10-K/A · filed 2022-03-04 |
| 2020-09-30 | $7.91M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $9.81M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $8.53M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $490.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $257.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $136.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $12.10M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $13.77M 10-K · filed 2020-03-02 |
| 2018-09-30 | $37.70M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $37.84M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $16.67M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |